Compare IQIYI Inc - ADR (IQ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Natera Inc. Common Stock — how do they compare? IQIYI Inc - ADR trades at $0.95 (market cap $962.85M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 59.2× IQIYI Inc - ADR's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Natera Inc. Common Stock for 0 Days on average.
| IQ | NTRA | |
|---|---|---|
Market Cap | $962.85M | $57.03B |
Volume | 8,833,890 | 1,131,157 |
Sector | Media | Health |
52-Week High | $2.35 | $425.64 |
52-Week Low | $0.86 | $179.42 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $2.46B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $0.9513, down 6.74% over 24 hours amid mixed signals. The stock shows a neutral technical stance with a bullish moving average trend but an overbought RSI. Fundamentally, the company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $27.29 billion. Analyst sentiment is split, with 50% recommending buy. Recent news highlights iQIYI's push into AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious; while AI initiatives offer growth potential, persistent losses and revenue contraction pose risks. Valuation metrics like a high P/E of 144.05 suggest premium pricing relative to earnings, but low P/S and P/B ratios may attract value investors. Key risks include competitive pressures in streaming and reliance on AI content monetization. Investors should weigh innovation bets against financial sustainability.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
